FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_					
\sim	MR	ΛD	ᇚ	A١	/ N I

OMB Number:	3235-0287
Estimated average burde	n
hours per response:	0.5

ı	Check this box if no longer subject to
l	Section 16. Form 4 or Form 5 obligations
I	may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* NEIL GARRY ARTHUR			2. Issuer Name and Ticker or Trading Symbol Avalo Therapeutics, Inc. [AVTX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 05/15/2023	X	Director Officer (give title below) CEO and Chairman of t	10% Owner Other (specify below)		
540 GAITHER ROAD, SUITE 400			4. If Amendment, Date of Original Filed (Month/Day/Year)	dual or Joint/Group Filing (Cher Form filed by One Reporting	o Filing (Check Applicable Line) ne Reporting Person			
ROCKVILLE			Rule 10b5-1(c) Transaction Indication		Form filed by More than One Reporting			
(City)	(State)	(Zip)	Check this box to indicate that a transaction was made pursuant to a contra affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.	ct, instructi	on or written plan that is intended	to satisfy the		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)	saction Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Stock Option (Right to Buy)	\$2.75	05/15/2023		A		100,000		05/15/2024 ⁽¹⁾	05/15/2033	Common Stock	100,000	\$0	100,000	D	

Explanation of Responses:

1. The stock option will vest in full on May 15, 2024, subject to the Reporting Person's continued service on such vesting date.

Remarks:

/s/ Jennifer Zoltoski, by Power of Attorney

05/16/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).